Anzupgo

Anzupgo is a steroid-free cream used to treat moderate to severe chronic hand eczema in adults. Anzupgo helps reduce inflammation and relieve symptoms such as redness, itching, and skin thickening. It is a prescription cream that can be used when eczema has not responded to a topical corticosteroid or when patients are unable to use them.

Anzupgo cream is applied twice daily in a thin layer to the hands and wrists.

Anzupgo (delgocitinib) works by blocking enzymes called Janus kinases (JAKs), which play an important role in the inflammatory processes that cause chronic hand eczema. Anzupgo's drug class is a JAK inhibitor.

Chronic hand eczema is a long-lasting inflammatory skin condition that affects the hands. It causes symptoms such as redness, itching, pain, dryness, cracking, and thickened skin. The condition is considered chronic when it lasts for three months or longer, or when it recurs at least twice within a year.

Anzupgo FDA approval was granted on July 23, 2025, after positive results from clinical trials DELTA 1 (NCT04871711), DELTA 2 (NCT04872101), and DELTA 3 (NCT04949841). Anzupgo improved itch, pain, and more patients scored their eczema as clear or almost clear compared to patients using the placebo cream. Eczema improvement was measured using Investigator’s Global Assessment for chronic hand eczema (IGA-CHE) at week 16.

Before using this cream, tell your healthcare provider if you:

• Have an infection, as using Anzupgo cream while you have an active infection may worsen your condition or interfere with healing.
• Have recently received or are planning to receive a vaccine as you should avoid live vaccines just before, during, or immediately after treatment with Anzupgo, as the medication may affect how well the vaccine works.

Pregnancy

Tell your healthcare provider if you are pregnant or planning to become pregnant, as it is not known whether Anzupgo cream can harm an unborn baby. Talk to your doctor before starting treatment.

Breastfeeding

Tell your healthcare professional if you are breastfeeding or intend to breastfeed, as it is unclear if Anzupgo passes into breast milk. Discuss with your healthcare professional about the best way to feed your baby during treatment. If you are breastfeeding while using Anzupgo, avoid direct contact between the treated area (hands and wrists) and the nipple or surrounding skin immediately after application.

Common Anzupgo side effects

The most common Anzupgo side effects include pain, tingling, itching, and redness at the application site; bacterial skin infections such as finger cellulitis and nail infections; and a decrease in white blood cell count.

Serious side effects

Increased Risk of Infections. This medicine may weaken your immune system and raise the risk of serious infections. These can include tuberculosis (TB), bacterial, viral, or fungal infections, some of which may be life-threatening. Conditions such as shingles (herpes zoster) or eczema herpeticum may also occur during treatment. Anzupgo should not be used if you have an active or serious infection, and treatment may need to be paused if a serious infection develops.

Before starting Anzupgo, tell your healthcare provider if you:

• are being treated for an infection
• have an infection that does not go away or that keeps coming back
• have TB or have been in close contact with someone with TB
• have had shingles (herpes zoster) have had hepatitis B or C
• think you have an infection or have symptoms of an infection such as:

After starting this medicine, tell your healthcare provider right away if you have any symptoms of an infection.

Non-Melanoma Skin Cancer. Use of Anzupgo may increase your risk of certain types of non-melanoma skin cancers. Regular skin checks are recommended. Patients should avoid sunlamps and minimize sun exposure by using sunscreen and protective clothing.

Potential risks from Janus kinase (JAK) inhibition. Anzupgo is a JAK inhibitor, and it is not known whether using Anzupgo has the same risks as taking other oral or topical JAK inhibitors. Increased risk of death (all causes) has happened in people who were 50 years of age and older with at least 1 heart disease (cardiovascular) risk factor who were taking a JAK inhibitor used to treat rheumatoid arthritis (RA) compared to people taking another medicine in a class of medicines called TNF blockers. Anzupgo is not for use in people with RA. Other oral or topical JAK inhibitors have also caused increased cholesterol. Low blood sugar in people with diabetes has happened after taking JAK inhibitors by mouth.

Apply Anzupgo cream twice daily in a thin layer to the affected areas of the hands and wrists.

Do not use the cream in or on your eyes, mouth, vagina or other mucous membranes. If contact with mucous membranes happens, rinse well with water.

Clean and dry the area before applying the cream.

Do not use more than 30 grams in 2 weeks or 60 grams in a month.

If you are applying Anzupgo to someone else, wash your hands thoroughly afterward.

Tell your healthcare provider about all medications you use, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.

Using this cream in combination with other JAK inhibitors or potent immunosuppressants is not recommended.

Store cream at room temperature between 68ºF to 77ºF (20ºC to 25ºC)

Active ingredient: delgocitinib

Inactive ingredients: benzyl alcohol, butylated hydroxyanisole, cetostearyl alcohol, citric acid monohydrate, edetate disodium, hydrochloric acid, mineral oil, polyoxyl 20 cetostearyl ether, and purified water.

Anzupgo LEO Laboratories Ltd., 285 Cashel Road, Dublin 12, Ireland